

Erratum

Prognostic value of Caspase-3 expression in cancers of digestive tract: a meta-analysis and systematic review: Int J Clin Exp Med. 2015; 8(7): 10225-10234

Hao Chen, Xia Yang, Zhenbo Feng, Ruixue Tang, Fanghui Ren, Kanglai Wei, Gang Chen

Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China

Received January 23, 2022; Accepted April 28, 2022; Epub May 15, 2022; Published May 30, 2022

In this article [1], one mistake was found. **Table 1** was partially incorrect. It should be corrected as follows. We are publishing this Erratum to reflect this change. The authors apologize for the mistake.

Address correspondence to: Dr. Gang Chen, Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China. E-mail: chen_gang_triones@163.com

Reference

- [1] Chen H, Yang X, Feng Z, Tang R, Ren F, Wei K and Chen G. Prognostic value of Caspase-3 expression in cancers of digestive tract: a meta-analysis and systematic review. Int J Clin Exp Med 2015; 8: 10225-34.

Prognostic value of Caspase-3 in digestive tract cancers

Table 1. Main characteristics and results of the eligible studies

First author	Year	Patients' source	tumor type	method	stage	number	caspase-3(+)	HR (95% CI)	P value
Jiang H [7]	2010	China	esophageal cancer	IHC	ND	64	51/64	OS 0.14 (0.03-0.6)	0.001
Hsia J Y [8]	2002	China	esophageal squamous cell carcinoma	IHC	UICC I-III	40	24/40	OS 0.52 (0.22-1.26)	0.02
Cao F M [9]	2005	China	esophageal squamous cell carcinoma	flow cytometry	TNM I-III	101	56/101	ND	0.014
Parenti A [10]	2005	Italy	Barrett's esophagus carcinogenesis	IHC	ND	40	35/40	ND	<0.001
Isobe N [11]	2004	Japan	gastric carcinoma	IHC	ND	151	78/151	OS 2.22 (1.08-4.56)	0.0301
Kim M A [12]	2011	Korea	gastric carcinoma	IHC	TNM I-IV	1162	730/1162	OS 0.56 (0.47-0.68)	<0.001
Xiao L J [13]	2013	Japan	gastric carcinomas	IHC	TNM 0-IV	499	292/499	OS 1.29 (0.96-1.74)	0.031
Li Y H [14]	2004	China	gastric carcinomas	IHC	UICC I-III	80	ND	ND	ND
Hector S [15]	2012	Ireland	colorectal cancer	IHC	Stage II-III	224	58/224	OS: II: 1.55 (0.29-8.38) III: 1.67 (0.77-3.66) RFS: II: 0.92 (0.23-3.74) III: 1.25 (0.65-2.41)	0.0662 0.7746 0.0052 0.9006
Meyer A [16]	2009	Germany	colon carcinomas	IHC	UICC: II-IV	392	230/392	OS 3.8 (1.2-12.4)	0.047
Dawson H [17]	2013	Switzerland	colorectal cancer	IHC	ND	188	ND	ND	0.0262
de Oca J [18]	2008	Spain	Colorectal cancer	IHC	ND	54	ND	OS 0.7 (0.31-1.55)	0.013
Guan J M [19]	2012	China	colorectal cancer	IHC	Duke A and B	72	25/54	ND	0.018
Koelink P J [20]	2009	Netherlands	colorectal cancer	IHC	Dukes' stage: A-D	211	105/211	OS: 0.69 (0.49-0.97) RFS: 1.77 (1.05-3.01) DFS: 0.69 (0.5-0.96)	0.04 0.02 0.04
Noble P [21]	2013	UK	colorectal tumor	IHC	ND	462	142/462	OS 0.81 (0.34-1.92)	0.629
de Heer P [22]	2007	Netherlands	Rectal Cancer	IHC	Stage III	117	59/117	OS 7.5 (1.7-34.1)	0.008